Video

Claire Jansson-Knodell, MD: Treating Pregnant Women With Celiac Disease

Author(s):

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

Pregnant women with celiac disease are at an increased risk of a number of negative outcomes, including preeclampsia, placental diseases, obstetric complications, and small for gestational age offspring.

In data presented during the 2023 Digestive Disease Week (DDW) in Chicago, a team of investigators studied outcomes within this patient population.

In the retrospective cohort study, the investigators sued the National Inpatient Sample for all pregnant women who delivered babies between 2015-2019, which included 12 million delivers, 10,555 of which were from women with celiac disease.

The results show pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery (odds ratio [OR], 0.15; 95% confidence interval [CI], 0.09-0.26) compared to the cohort without celiac disease.

However, there was not much of a difference in maternal mortality between the 2 groups [n = 0; 0% vs n = 895; <0.1%; P = 0.7].

For offspring, babies of celiac moms were more likely to be small for gestational age (OR, 1.26; 95% CI, 1.01-1.57) and experience distress (OR, 1.29; 95% CI, 1.17-1.42) during delivery.

In an interview with HCPLive®, Claire Jansson-Knodell, MD, associate staff, Cleveland Clinic, explained what the advice is for pregnant women with celiac disease in an effort to reduce the risk of these types of outcomes.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.